Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

ENLV


Top 10 Correlated ETFs

ENLV


Top 10 Correlated Stocks

ENLV


In the News

02:08 03 Oct 2022 ENLV

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Enlivex Therapeutics: The early results for Allocetra for sepsis (in humans) and solid tumors (in mice) look incredible. The share offering from 2021 shows a willingness to protect existing shareholders.

08:00 03 Oct 2022 ENLV

Enlivex to Present at the 2022 Jefferies Healthcare Conference

Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that company management will present a corporate update at the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY. The presentation will take place on June 9, 2022, at 1:00 PM Eastern Time. A webcast of the presentation will be available at https://wsw.com/webcast/jeff240/enlv/1853925 , and will be archived for 90 days.

10:48 03 Oct 2022 ENLV

Enlivex Therapeutics Stock (ENLV): Why The Price Increased Today

The stock price of Enlivex Therapeutics Ltd (NASDAQ: ENLV) increased by over 4% during intraday trading today. This is why it happened.

08:00 03 Oct 2022 ENLV

Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine

Publication follows the Israeli Ministry of Health's appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines

08:48 03 Oct 2022 ENLV

Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021

Nes-Ziona, Israel, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the Reuters Events' Cell & Gene Therapy USA 2021 event, which is taking place virtually on September 28 and 29, 2021.

07:45 03 Oct 2022 ENLV

Enlivex Therapeutics (ENLV) Sees Hammer Chart Pattern: Time to Buy?

Enlivex Therapeutics (ENLV) has been struggling lately, but the selling pressure may be coming to an end soon.

11:27 03 Oct 2022 ENLV

Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy

Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.

06:00 03 Oct 2022 ENLV

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS



08:00 03 Oct 2022 ENLV

Enlivex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Nes-Ziona, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that Company management will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

01:45 03 Oct 2022 ENLV

Here's Why Enlivex Therapeutics Ltd. (ENLV) is a Great Momentum Stock to Buy

Does Enlivex Therapeutics Ltd. (ENLV) have what it takes to be a top stock pick for momentum investors?

Financial details

Company Rating
Neutral
Market Cap
78.12M
Income
-19.49M
Revenue
0
Book val./share
4.23
Cash/share
4.25
Dividend
-
Dividend %
-
Employees
71
Optionable
No
Shortable
Yes
Earnings
19 Nov 2021
P/E
-4.01
Forward P/E
-
PEG
-2.14
P/S
-
P/B
1.01
P/C
1
P/FCF
-3.74
Quick Ratio
13.79
Current Ratio
13.81
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.07
EPS next Y
-
EPS next Q
-
EPS this Y
22.07%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
74%
-
-
-
-
SMA20
-20.4%
SMA50
-9.03%
SMA100
-7.48%
Inst Own
3.3%
Inst Trans
-1.32%
ROA
-22%
ROE
-23%
ROC
-0.26%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
18.38M
Shs Float
14.66M
-
-
-
-
Target Price
15
52W Range
3.65-9.85
52W High
-52.78%
52W Low
+41.67%
RSI
38.46
Rel Volume
0.14
Avg Volume
46.94K
Volume
6.35K
Perf Week
-5.97%
Perf Month
-15.17%
Perf Quarter
-47.66%
Perf Half Y
-25.63%
-
-
-
-
Beta
0.414285
-
-
Volatility
0.11%, 0.48%
Prev Close
2.66%
Price
4.25
Change
1.19%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
00000
Net income per share
-14.35-9.67-8.68-0.9-1.1
Operating cash flow per share
-15.34-7.21-6.51-0.84-1.33
Free cash flow per share
-15.34-8.26-6.69-0.91-1.46
Cash per share
8.5122.2911.112.716.39
Book value per share
7.6322.1310.432.696.46
Tangible book value per share
7.6322.1310.062.696.46
Share holders equity per share
7.6322.1310.432.696.46
Interest debt per share
000.110.020.05
Market cap
9.11M3.65M8.82M157.37M67.82M
Enterprise value
5.59M-6.09M5M151.9M57.24M
P/E ratio
-1.53-0.86-0.94-13.31-4.69
Price to sales ratio
00000
POCF ratio
-1.43-1.15-1.25-14.3-3.87
PFCF ratio
-1.43-1.01-1.22-13.09-3.54
P/B Ratio
2.880.380.784.430.8
PTB ratio
2.880.380.784.430.8
EV to sales
00000
Enterprise value over EBITDA
-0.951.18-0.59-20.98-2.41
EV to operating cash flow
-0.881.93-0.71-13.8-3.26
EV to free cash flow
-0.881.68-0.69-12.63-2.99
Earnings yield
-0.65-1.16-1.06-0.08-0.21
Free cash flow yield
-0.7-0.99-0.82-0.08-0.28
Debt to equity
00000
Debt to assets
0.130.120.360.120.11
Net debt to EBITDA
0.61.880.450.760.45
Current ratio
7.879.092.758.7218.32
Interest coverage
00000
Income quality
1.070.750.750.931.21
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
000.0200
Capex to operating cash flow
00.150.030.090.09
Capex to revenue
00000
Capex to depreciation
-0.03-3.81-0.94-3.56-2.98
Stock based compensation to revenue
00000
Graham number
49.6569.3845.147.3812.63
ROIC
-1.88-0.54-0.74-0.27-0.21
Return on tangible assets
-1.64-0.38-0.55-0.29-0.15
Graham Net
7.4519.626.972.345.75
Working capital
3.16M9.15M10.44M33.75M81.72M
Tangible asset value
0010.87M00
Net current asset value
3.16M8.95M10.14M33.25M76.34M
Invested capital
000.010.010.01
Average receivables
00000
Average payables
241K318K389.5K463K670.5K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-1.88-0.44-0.83-0.33-0.17
Capex per share
0-1.05-0.18-0.08-0.12

Quarterly Fundamentals Overview

Last date of statement is 2022-03-31 for Q1

Metric History 2021-03-312021-06-302021-09-302021-12-31 2022-03-31
Revenue per share
00000
Net income per share
-0.19-0.17-0.19-0.26-0.45
Operating cash flow per share
-0.14-0.24-0.23-0.36-0.18
Free cash flow per share
-0.15-0.26-0.24-0.42-0.23
Cash per share
5.564.954.794.594.25
Book value per share
5.54.934.814.644.23
Tangible book value per share
5.54.934.814.644.23
Share holders equity per share
5.54.934.814.644.23
Interest debt per share
0.010.010.030.030.04
Market cap
182.76M162.92M180.93M114.45M102.69M
Enterprise value
178.88M150.52M159.42M103.87M35.72M
P/E ratio
-14.28-13.11-13.21-6.04-3.12
Price to sales ratio
00000
POCF ratio
-78.1-36.94-43.07-17.36-31.41
PFCF ratio
-72.73-34.6-41.87-15.01-24.33
P/B Ratio
2.021.812.051.351.32
PTB ratio
2.021.812.051.351.32
EV to sales
00000
Enterprise value over EBITDA
-48.54-40.84-43-13.55-5.75
EV to operating cash flow
-76.44-34.13-37.95-15.76-10.93
EV to free cash flow
-71.18-31.96-36.89-13.62-8.46
Earnings yield
-0.02-0.02-0.02-0.04-0.08
Free cash flow yield
-0.01-0.03-0.02-0.07-0.04
Debt to equity
00000
Debt to assets
0.060.050.10.110.12
Net debt to EBITDA
1.053.365.81.3810.77
Current ratio
19.1120.2919.0818.3213.81
Interest coverage
00000
Income quality
0.731.421.231.390.4
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.070.070.030.160.29
Capex to revenue
00000
Capex to depreciation
-1.48-2.45-0.76-6.89-5.06
Stock based compensation to revenue
00000
Graham number
4.94.344.55.26.53
ROIC
-0.04-0.04-0.04-0.09-0.08
Return on tangible assets
-0.03-0.03-0.03-0.05-0.09
Graham Net
5.244.734.314.133.7
Working capital
88.87M88.25M85.55M81.72M73.56M
Tangible asset value
00000
Net current asset value
88.42M87.85M80.2M76.34M68.33M
Invested capital
000.010.010.01
Average receivables
01.77M1.99M2.2M1.69M
Average payables
612.5K718K970K878K1.12M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.04-0.03-0.04-0.06-0.11
Capex per share
-0.01-0.02-0.01-0.06-0.05

Frequently Asked Questions

What is Enlivex Therapeutics Ltd. stock symbol ?

Enlivex Therapeutics Ltd. is a IL stock and trading under the symbol ENLV

Is Enlivex Therapeutics Ltd. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $15. The lowest prediction is $15 and the highest is $15

What is ENLV stock prediction ?